Can l-carnitine reduce post-COVID-19 fatigue?

Abstract

A significant number of patients infected with the new coronavirus suffer from chronic fatigue syndrome after COVID-19, and their symptoms may persist for months after the infection. Nevertheless, no particular treatment for post-disease fatigue has been found. At the same time, many clinical trials have shown the effectiveness of l -carnitine in relieving fatigue caused by the treatment of diseases such as cancer, MS, and many other diseases. Therefore, it can be considered as a potential option to eliminate the effects of fatigue caused by COVID-19, and its consumption is recommended in future clinical trials to evaluate its effectiveness and safety.

Efficacy of oseltamivir in the treatment of patients infected with Covid-19

“…This new virus is the seventh human coronavirus described to date as responsible for respiratory infections [ 2 ], and is classified into the beta coronavirus subgroup [ 3 , 4 ].…”

Acute disseminated encephalitis (ADEM) as the first presentation of COVID-19; a case report

“…One of the potential underlying mechanisms of ADEM in association with SARS-CoV-2 is the cytokine pathway activation, which is known to be involved in the pathology of ADEM. It has been stated to result from T cells affected by SARS-CoV-2 inducing a storm of cytokines, especially IL-6 [ [16] , [17] , [18] ]. This results in sequences of immune responses that may play an important role in the pathogenesis of ADEM [ 19 ].…”

Acute retroperitoneal hematoma following severe Covid-19 and the use of anticoagulants

“…Intake of anticoagulants is known for increased risk of hematoma [ 8 , 9 ]. A few case studies have reported similar in severe COVID19 patients [ 10 ]. In this case series, we present COVID19 patients who were treated with anticoagulants and were seen to be presented with retroperitoneal hematoma.…”